At Intellia, we are building a full-spectrum, product-driven biotechnology company focused on developing and commercializing potentially curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. Our approach to advancing the broad potential of genome editing includes our plans to:
On the in vivo side, our systemic lipid nanoparticle or LNP-based delivery system, has the potential to unlock treatment of genetic diseases to both selectively knock out disease-causing genes and introduce targeted insertion of a functional gene.
We are also focused on engineering T cell therapies to preserve normal cell physiology. Our approach is designed to improve safety and efficacy by engineering cell therapies that are more precise, potent and persistent.